INVO Bioscience Performance
| INVODelisted Stock | USD 0.84 0.03 3.45% |
On a scale of 0 to 100, INVO Bioscience holds a performance score of 4. The company retains a Market Volatility (i.e., Beta) of -2.92, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning INVO Bioscience are expected to decrease by larger amounts. On the other hand, during market turmoil, INVO Bioscience is expected to outperform it. Please check INVO Bioscience's potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether INVO Bioscience's current trending patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in INVO Bioscience are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, INVO Bioscience displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 90.1 K |
INVO |
INVO Bioscience Relative Risk vs. Return Landscape
If you would invest 78.00 in INVO Bioscience on August 28, 2024 and sell it today you would earn a total of 6.00 from holding INVO Bioscience or generate 7.69% return on investment over 90 days. INVO Bioscience is currently generating 0.7388% in daily expected returns and assumes 13.1793% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than INVO, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
INVO Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for INVO Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as INVO Bioscience, and traders can use it to determine the average amount a INVO Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0561
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | INVO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.18 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.74 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average INVO Bioscience is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of INVO Bioscience by adding it to a well-diversified portfolio.
INVO Bioscience Fundamentals Growth
INVO Stock prices reflect investors' perceptions of the future prospects and financial health of INVO Bioscience, and INVO Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on INVO Stock performance.
| Return On Equity | -143.59 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.23) % | |||
| Operating Margin | (1.04) % | |||
| Current Valuation | 15.19 M | |||
| Shares Outstanding | 3.91 M | |||
| Price To Book | 5.97 X | |||
| Price To Sales | 0.56 X | |||
| Revenue | 3.02 M | |||
| EBITDA | (6.63 M) | |||
| Cash And Equivalents | 1.96 M | |||
| Cash Per Share | 0.16 X | |||
| Total Debt | 8.68 M | |||
| Debt To Equity | 0.60 % | |||
| Book Value Per Share | (1.59) X | |||
| Cash Flow From Operations | (4.76 M) | |||
| Earnings Per Share | 0.69 X | |||
| Total Asset | 20.89 M | |||
| Retained Earnings | (57.82 M) | |||
About INVO Bioscience Performance
By examining INVO Bioscience's fundamental ratios, stakeholders can obtain critical insights into INVO Bioscience's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that INVO Bioscience is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. The company was founded in 2007 and is based in Sarasota, Florida. Invo Bioscience operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.Things to note about INVO Bioscience performance evaluation
Checking the ongoing alerts about INVO Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for INVO Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| INVO Bioscience is now traded under the symbol NAYA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| INVO Bioscience is not yet fully synchronised with the market data | |
| INVO Bioscience is way too risky over 90 days horizon | |
| INVO Bioscience has some characteristics of a very speculative penny stock | |
| INVO Bioscience appears to be risky and price may revert if volatility continues | |
| INVO Bioscience has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.02 M. Net Loss for the year was (8.03 M) with profit before overhead, payroll, taxes, and interest of 535.27 K. | |
| INVO Bioscience currently holds about 1.96 M in cash with (4.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16. |
- Analyzing INVO Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether INVO Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining INVO Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating INVO Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of INVO Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of INVO Bioscience's stock. These opinions can provide insight into INVO Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in INVO Stock
If you are still planning to invest in INVO Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the INVO Bioscience's history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |